All of the folloiwng statements about Ranolazine are true, except;
Ans. is 'd' i.e., Hypotension is an established adverse effect Ranolazine is an effective newer anti-anginal drug but unlike CCBs and beta-blockers it does not significantly alter the hea rate or blood pressure. It is a piperazine derivative. o Ranolazine appears to have other promising non-anginal effects, including glycemic control, improvement in endothelial function and decreases the incidence of atrial fibrillation and other arrhythmias. o Ranolazine has been generally well tolerated in clinical trials its most common adverse effects are nausea, constipation and dizziness. About option b o Most of the text books have mentioned that ranolazine can be used as add-on therapy in chronic stable angina. o However, it has recently been approved as first line agent: " Previously limited by its FDA indication to use in angina in combination with a calcium channel blocker, beta blocker or nitrate; ranolazine is now approved for use as a first line agent in chronic angina". .. The Hea. org.
Piperazine derived antianginal agent
May be used as first line agent in chronic angina
May improve glycemic control
Hypotension is an established adverse effect